Molbio Diagnosti

Which are the latest news on Molbio Diagnosti?

Why is Molbio Diagnostics Ltd falling/rising?

As of 05-Sep, Molbio Diagnostics Ltd's stock price is rising to 1,162.35, reflecting a 2.5% increase and strong recent performance with a total return of 10.37% over three days. Despite a decline in investor participation, the stock remains above its moving averages, indicating a positive trend.

As of 05-Sep, Molbio Diagnostics Ltd's stock price is rising, currently at 1,162.35, which reflects an increase of 28.35 (2.5%). The stock has shown strong performance recently, outperforming the sector by 3.76% today and achieving a consecutive gain over the last three days with a total return of 10.37% during this period. Additionally, the stock reached an intraday high of Rs 1175, marking a rise of 3.62%. <BR><BR>The stock is also trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a positive trend. However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 49.16% compared to the 5-day average. Despite this decrease in participation, the liquidity remains adequate for trading. Overall, the combination of recent gains, positive performance relative to the sector, and favorable moving averages contributes to the stock's rising price.

When is the next results date for Molbio Diagnostics Ltd?

The next results date for Molbio Diagnostics Ltd is September 5, 2026.

The next results date for Molbio Diagnostics Ltd is scheduled for September 5, 2026.

What does Molbio Diagnosti do?

Molbio Diagnostics Ltd is a mid-cap company in the healthcare services industry, with a market cap of INR 12,590 Cr. Key financial metrics include a P/E ratio of 86.00, a debt-equity ratio of -0.09, and a return on equity of 14.78%.

Overview: <BR>Molbio Diagnostics Ltd operates in the healthcare services industry and is categorized as a mid-cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not available. The latest quarter for which sales and profit are reported is also not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 12,590 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 86.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 14.78% <BR>Price-to-Book: 12.77<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Molbio Diagnosti?

Molbio Diagnosti's peers include Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Suven Life Scie., Thyrocare Tech., and Vimta Labs. Key insights show excellent management risk at Dr Lal Pathlabs and Thyrocare Tech., with Vijaya Diagnost. leading in 1-year returns at 50.91%, while Syngene Intl. has the lowest at -35.90%.

Peers: The peers of Molbio Diagnosti are Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Suven Life Scie., Thyrocare Tech., and Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Thyrocare Tech., while Good management risk is found at Poly Medicure, Syngene Intl., Vijaya Diagnost., and the rest. Average management risk is present at Indegene, Metropolis Healt, and Vimta Labs, while Below Average management risk is noted at Suven Life Scie. Growth is consistently Below Average across all peers. Excellent capital structure is seen at Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., Thyrocare Tech., and Vimta Labs, while Average capital structure is found at Indegene and Metropolis Healt, and Below Average capital structure is noted at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vijaya Diagnost. at 50.91%, while Syngene Intl. has the lowest at -35.90%. Molbio Diagnosti's 1-year return is not available for comparison. Additionally, Syngene Intl. and Molbio Diagnosti are among the peers with negative six-month returns.